BMS and California Institute for Biomedical Research Sign Worldwide Research Collaboration and License Agreement
Bristol-Myers Squibb Company (BMS) and the California Institute for Biomedical Research (Calibr) have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive licence agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration.
“BMS’s collaboration with Calibr further strengthens our Specialty portfolio and advances the company’s fibrotic diseases pipeline with the addition of this promising programme,” said Carl Decicco, Head of Discovery, R&D, BMS. “Calibr’s innovative discovery programme in fibrosis represents an opportunity to develop new treatment approaches for patients.”
“Progressing our small molecule anti-fibrotic programme toward the clinic represents a critical step in our mission to deliver therapies for unmet medical needs to patients,” said Peter G. Schultz, Institute Director and Founder of Calibr. “We are delighted to accelerate these efforts by partnering with BMS.”
Identifying novel medicines to halt or slow the progression of fibrotic disease and improve upon the current standard of care is a key part of BMS’s R&D strategy. Calibr, an independent, not-for-profit organization established to accelerate the translation of basic biomedical discoveries into innovative new medicines, brings to the collaboration substantial expertise in identifying and optimizing small molecules with anti-fibrotic activity through its high-throughput screening, target identification, and preclinical drug discovery infrastructure.
BMS is committed to addressing the unmet need in fibrosis, a strategic area of focus for the company, by identifying novel medicines to halt or slow the progression of fibrotic disease. Among the assets in BMS’s fibrosis portfolio are BMS-986020, a lysophosphatidic acid 1 (LPA1) receptor antagonist in Phase II development for the treatment of idiopathic pulmonary fibrosis (IPF), and a CCR2/5 dual antagonist in Phase II development for diabetic kidney disease. In November, 2014, BMS and Galecto Biotech AB announced, together with the Galecto shareholders, an agreement that provides BMS the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase I development for the treatment of IPF and other pulmonary fibrotic conditions.
BMS and Calibr anticipate that the transaction will close during the first quarter of 2015. Closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Financial terms of the agreement were not disclosed.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance